Abstract 5555
Background
In RAS wild type metastatic colorectal cancer patients (pts), high tumor expression of microRNA miR-31-3p and miR-31-5p has been associated with poorer benefit of anti-EGFR therapy. miR-31-3p expression has been shown to be predictive of treatment effect in the FIRE-3 trial. The PETACC-8 phase III trial assessed the efficacy of cetux addition to FOLFOX compared to FOLFOX only in pts with resected stage III colon cancer (CC). The primary end point was negative, but a trend towards benefit of cetux on disease free survival (DFS) was observed in pts with RAS/BRAF wild type (WT) tumors. The current study aimed at assessing miR-31-3p and 5p tumor levels as prognostic and predictive biomarkers of adjuvant cetux benefit in these pts.
Methods
miR-31-3p and 5p levels were measured by RT-qPCR from 477 WT pts tumor RNA. The primary objective was to demonstrate a benefit of cetux on DFS for low miR-31-3p expressers. Cox regression model was used for univariate and multivariate analyses. Optimal cut-off values for low and high expressers were determined post hoc.
Results
In the studied population, cetux benefit was significant for DFS (HR = 0.71 [0.50;1.00] p = 0.05) but not for Overall Survival (OS) (HR = 0.79 [0.53;1.18] p = 0.25). Expression of miR-31-3p and miR-31-5p were highly correlated (R > 0.9). Higher miR-31-3p and 5p expression were associated with shorter DFS and OS (p < 0.01). Pts with low miR-31-3p levels (n = 218/435, 50%) had a non-significant benefit from cetux on DFS (HR 0.61 [0.33; 1.11] p = 0.10) and OS (HR = 0.67 [0.33; 1.35] p = 0.26). Pts with low miR-31-5p levels (n = 233/477, 49%) benefited from cetux on DFS (HR = 0.46 [0.25; 0.84] p = 0.01) and OS (HR = 0.50 [0.25; 0.99], p = 0.047) whereas high expressers did not (DFS: HR = 0.87 [0.56; 1.34] ; OS: HR = 1.01 [0.61; 1.67]). miR-31-5p was predictive of treatment effect on DFS at the 10% level (interaction tests: p = 0.09 for DFS and p = 0.103 for OS). Results were still significant after adjustment for clinical covariates.
Conclusions
In pts with resected stage III WT CC, miR-31-3p and 5p were prognostic of DFS and OS. Pts with low miR-31 expression benefited from cetux addition to FOLFOX for adjuvant therapy, and miR-31-5p was predictive of cetux efficacy.
Clinical trial identification
NCT03362684.
Legal entity responsible for the study
IntegraGen SA.
Funding
IntegraGen.
Editorial Acknowledgement
Disclosure
Y. Gaston Mathe: Ex employee: IntegraGen. S. Martin-Lannerée, C. Vazart, K. Fontaine: Employee: IntegraGen. A. Caumont, F. Montestruc: Consultant: IntegraGen. J. Taieb: Honoraria: Lilly, Celgene, Servier, Amgen, Roche, Merck, Sirtex, Sanofi. P. Laurent-Puig: Honoraria: IntegraGen, Merck-Serono, Amgen, Boehringer-Ingelheim, Roche, Lilly, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract